Boston, United States
DermBiont, Inc., founded in 2017, is pioneering advancements in precision dermatology with a focus on Biotechnology, Health Care, and Health and Wellness. Their approach focuses on developing and commercializing targeted topical therapeutics, with the aim of treating, curing, and preventing skin diseases. Central to their mission is addressing the root causes of skin conditions using targeted small molecule therapeutics and biotherapeutics aimed at microbiome repair.
The company boasts a robust pipeline, including treatments such as SM-020 for seborrheic keratosis, SM-030 for hyperpigmentation disorders, and DBI-001 & DBI-002 for atopic dermatitis, tinea pedis, and onychomycosis. Based in the United States, DermBiont recently secured a $35.20M Series B investment on 19 October 2023, with backing from notable investors like Civilization Ventures, Olive Tree Capital, and Viking Global Investors. This capital injection underscores investor confidence in DermBiont’s vision and potential impact in the dermatological field.
